Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

PLGA-nanoparticles loaded with a thiosemicarbazone derived palladium(ii) complex as a potential agent to new formulations for human ovarian carcinoma treatment

Full text
Oliveira, Carolina G. [1, 2] ; Dalmolin, Luciana F. [3] ; Silva, R. T. C. [2, 4] ; Lopez, V, Renata F. ; Maia, Pedro I. S. [2, 4] ; Moreto, Jeferson A. [2, 4]
Total Authors: 6
[1] Fed Univ Uberlandia UFU, Inst Chem, BR-38400902 Uberlandia, MG - Brazil
[2] Fed Univ Triangulo Mineiro UFTM, Inst Exact Sci Nat & Educ, Ave Doutar Randolfo Borges Jr, BR-38064200 Uberaba, MG - Brazil
[3] V, Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, BR-14040903 Ribeirao Preto, SP - Brazil
[4] Univ Fed Triangulo Mineiro, Nucleo Desenvolvimento Compostos Bioat NDCBio, Av Dr Randolfo Borges 1400, BR-38025440 Uberaba, MG - Brazil
Total Affiliations: 4
Document type: Journal article
Source: NEW JOURNAL OF CHEMISTRY; v. 44, n. 35, p. 14928-14935, SEP 21 2020.
Web of Science Citations: 0

The complex named triphenylphosphane-chlorido(pyrenecarboxaldehyde-N(3)-cyclohexyl-thiosem icarbazonate)palladium(ii), {[}PdCl(PPh3)(PrCh)], has been recently selected as a promising cytotoxic agent against resistant ovarian cancer cells owing to its inhibitory effect on the topoisomerase IB enzyme. In order to increase the efficacy of this promising drug, in the present work the influence of the encapsulation process of the Pd(II)complex in the poly(lactic-co-glycolic acid) (PLGA) polymer was studied. PLGA nanoparticles containing the Pd(II)complex (NPs-PLGA-Pd-II) were prepared by using an emulsion-solvent evaporation technique and fully characterized by using DLS and SEM. The results showed that the NPs-PLGA containing the Pd(II)complex can be obtained successfully through an emulsion-solvent evaporation method with a high encapsulation efficiency (96%). Furthermore, the NPs-PLGA were revealed to be suitable as a controlled release carrier system for {[}PdCl(PPh3)(PrCh)], sincein vitrotests displayed a slow and sustained release of the Pd(II)complex. After Pd(II)encapsulation in NPs-PLGA, biological studies were assayed by using the OVCAR3 cell line (human ovarian carcinoma cells). The study of cytotoxicity by resazurin assay showed that the formulation led to a significant reduction of the ovarian cell viability (80% at 1 mu M), which was more than that achieved with the non-encapsulated complex or cisplatin. Most notably, the relevant cytotoxicity of NPs-PLGA-Pd(II)against the cisplatin resistant cell line used in this work must be highlighted since resistance is one of the major challenges in chemotherapy. (AU)

FAPESP's process: 14/22451-7 - Sustained drug delivery systems targeting the epithelial tissue
Grantee:Renata Fonseca Vianna Lopez
Support type: Research Projects - Thematic Grants